Table 1 General characteristics of study population.

Variables	Total		Glaucoma operation				P-value
	Total		No		Yes
	N	(%)	N	(%)	N	(%)
Prescribed glaucoma eyedrops							< 0.001
None	817	19.0	813	99.5	4	0.5
PG	1296	30.1	1243	95.9	53	4.1
Non-PG	1508	35.1	1440	95.5	68	4.5
Two or more	682	15.9	581	85.2	101	14.8
Oral CAI intake							< 0.001
No	3974	92.4	3796	95.5	178	4.5
Yes	329	7.7	281	85.4	48	14.6
Age group							0.005
< 45	782	18.2	751	96.0	31	4.0
45–54	775	18.0	749	96.7	26	3.4
55–64	1049	24.4	986	94.0	63	6.0
65 +	1697	39.4	1591	93.8	106	6.3
Sex							0.091
Men	1996	46.4	1904	95.4	92	4.6
Women	2307	53.6	2173	94.2	134	5.8
Income							0.088
Medical aids	386	9.0	372	96.4	14	3.6
Low	707	16.4	672	95.1	35	5.0
Middle	1265	29.4	1183	93.5	82	6.5
High	1945	45.2	1850	95.1	95	4.9
Residential area							0.012
Capital area	1993	46.3	1907	95.7	86	4.3
Metropolitan area	974	22.6	907	93.1	67	6.9
Rural area	1336	31.1	1263	94.5	73	5.5
Disability							0.123
No	3836	89.2	3627	94.6	209	5.5
Yes	467	10.9	450	96.4	17	3.6
Hypertension Hx							0.966
No	3680	85.5	3486	94.7	194	5.3
Yes	623	14.5	591	94.9	32	5.1
Diabetes Hx							0.191
No	3484	81.0	3293	94.5	191	5.5
Yes	819	19.0	784	95.7	35	4.3
Charlson Comorbidity Index							0.950
0	1948	45.3	1844	94.7	104	5.3
1	1451	33.7	1373	94.6	78	5.4
2	642	14.9	611	95.2	31	4.8
3 +	262	6.1	249	95.0	13	5.0
Total	4303	100.0	4077	94.8	226	5.3

PG: Prostaglandin analogue; CAI: Carbonic anhydrase inhibitor; Hx: History, *P-values were calculated using Chi-square test. Indicated in bold type, P < 0.05 indicates statistical significance.

Quick links

Search